A phase 1b, multi-center, open-label trial of evaluating pharmacokinetic profile of RA101495 in patients with renal impairment
Latest Information Update: 03 Oct 2018
At a glance
- Drugs Zilucoplan (Primary)
- Indications Haemolytic uraemic syndrome; Lupus nephritis
- Focus Pharmacokinetics
- Sponsors Ra Pharmaceuticals
- 26 Sep 2018 Results presented in a Ra Pharmaceuticals Media Release.
- 09 May 2018 According to a Ra Pharmaceuticals media release, eleven patients have been dosed to date and results are expected mid-2018.
- 08 Jan 2018 According to a Ra Pharmaceuticals media release, the company has initiated dosing subjects with renal impairment in this trial.